Indications
In combination with a 5-HT3 receptor antagonist and a corticosteroid, EMEND can be used in a wide range of patients receiving chemotherapy.
EMEND, in combination with other antiemetic agents, is indicated for prevention of:
- Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
- Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Important Safety Information
EMEND and EMEND for Injection, in combination with other antiemetic agents, are indicated in adults for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
EMEND and EMEND for Injection have not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND or EMEND for Injection is not recommended.
Selected Important Safety Information
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
PRIVACY POLICY